Navigation Links
CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments
Date:12/12/2012

Bloomfield Hills, MI (PRWEB) December 12, 2012

The LIVESTRONG BLOG says the newly launched website takes direct action by providing information on emerging treatments, access to the researchers involved, and actual enrollment to over 500 breast cancer medical research trials. It also gives anyone a direct chance to get involved in funding this research through use of the “crowdfunding” model that has taken the startup world by storm.

Naveen writes “as some involved in the fight against cancer know all too well, one of the most complicated crossroads in the journey is the clinical trials process”. At the recent MAGI Clinical Research Conference in San Diego, it was reported that of the 50,000 clinical trials that took place in the U.S. in 2009, 80 percent were delayed by at least a month due to low enrollment”.

Stephen Goldner, cureLauncher’s Founder and President, was a featured speaker at the Clinical Research conference. “Providing easy access for patients to connect with clinical trials is critical", said Goldner.

Only cureLauncher translates the complex, medical terminology into easy to understand English. It provides the entry questions to determine if a clinical trial is appropriate for anyone’s specific condition. People can submit a Request Form to participate in the trial or call CureLauncher directly to see if they qualify. CureLauncher is free to all users and a concierge person is available to answer any questions.    

CureLauncher is also supporting a new breast cancer treatment from esteemed cancer researcher Dr. Lee Roy Morgan. People can find information about this experimental treatment at cureLauncher and make a donation to advance the treatment. Ninety one percent of the donations go directly to advancing the new drug. Each person who donates $25 or more can email Dr. Morgan directly and receive his confidential reply.

CureLauncher’s Vice President, David Fuehrer, spoke with Naveen. "My connection to the LIVESTRONG Foundation is both professional and very personal. “At 25, I was a natural bodybuilding champion in New York. Four months later, I was diagnosed with testicular cancer”, said David.

“Lance Armstrong’s book helped me cope with my transition from competitive athlete to cancer patient. Five years later, I was diagnosed with testicular cancer a second time. Throughout the past 10 years, the LIVESTRONG Foundation has helped me accept myself and take action. That inspiration is a big part of why I work with cureLauncher to fund new cancer treatments to save lives”.

To learn more about breast cancer clinical trials or make a donation to the new breast cancer treatment, visit http://www.curelauncher.com
About CureLauncher
CureLauncher is an online platform that advances new cancer treatments. It connects patients to cures and cancer researchers to funding. CureLauncher brings leading cancer researchers and donors together to fund new cures.

Read the full story at http://www.prweb.com/releases/cureLauncher/LIVESTRONG_BLOG/prweb10230062.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. CureLauncher is a New Website That Connects Patients to Trials Across the U.S.
2. Only 16% of Donations go to New Cancer Treatments in Some Charities. With cureLauncher, 91% of Contributions Go Directly to New Cures for Cancer.
3. Nano-FTIR - A new era in modern analytical chemistry
4. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
5. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
6. Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform
7. Automated Online Sample Preparation Comes to Waters UltraPerformance Liquid Chromatography (UPLC) Platform
8. New Crowdfunding Platform, ScitechStarter, Focuses on Science and Technology Innovators
9. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
10. New England Cord Blood Bank chooses Sepax 2 from Biosafe as their Cord Blood Processing Platform
11. New Report: "Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance" Now Available at Twease.org
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on ... of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ... is expected to deliver therapeutic levels of olanzapine for a period of 3 months., ...
(Date:2/24/2017)... SAN DIEGO , Feb. 24, 2017  Aethlon ... the following note authored by its Chairman and CEO, ... address at the Munich Security Conference last Saturday, ... engineered virus could kill more people than nuclear weapons. ... by U.S. and U.K. intelligence agencies, that scientific terrorists ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell ... unaudited financial results for the third quarter and first ... 2016. Third Quarter of Fiscal 2017 Highlights ... fiscal 2017 increased by 18.6% to RMB200.9 million ($28.9 ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
Breaking Biology Technology:
(Date:2/9/2017)... , Feb. 9, 2017 The biomass boiler ... of the biomass boiler market globally in terms of ... biomass boilers. The market for biomass boilers has been ... end-user, application, and country/region. The market based on feedstock ... forest residues, biogas & energy crops, urban residues, and ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 The ... largely by the confluence of organizations, desires to ... for knowledge-based systems (password and challenge questions), biometrics ... and government systems. The market is driven by ... demarcation between consumer and enterprise uses cases, with ...
Breaking Biology News(10 mins):